Sunshine Biopharma, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Although the request metadata refers to 2023 Q4, this is an annual report, not a quarterly filing. The company’s commercial business is primarily Canadian generic pharmaceuticals through Nora Pharma; it also sells OTC products and is developing proprietary drug candidates.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | $24.09 million | $4.35 million |
| Cost of sales | $15.75 million | $2.65 million |
| Gross profit and margin | $8.34 million; approximately 34.6% | $1.70 million; approximately 39.0% |
| Operating loss | $4.79 million | $27.00 million |
| Net loss | $4.51 million; $0.19 per share | $26.74 million; $1.76 per share |
| Cash used in operating activities | $8.78 million | $5.25 million |
| Cash and cash equivalents | $16.29 million | $21.83 million |
| Total assets / total liabilities | $27.35 million / $6.14 million | $29.24 million / $7.62 million |
- Revenue increased substantially because 2023 includes a full year of Nora Pharma, acquired October 20, 2022; 2022 included only 72 days of its sales. Generic pharmaceuticals accounted for approximately 97% of FY2023 revenue, with OTC products contributing approximately 3%.
- FY2023 gross margin was approximately 34.6%; net margin was approximately negative 18.7%. G&A was $13.12 million, versus $28.70 million in 2022; the 2022 figure included an $18.33 million goodwill impairment. Excluding that impairment, G&A increased by approximately $2.75 million, which management attributed chiefly to a full year of Nora Pharma expenses.
- Cash declined by approximately $5.53 million year over year. The company reported a $8.78 million operating cash outflow and $3.43 million in cash provided by financing. Working capital was approximately $19.34 million; the current ratio was approximately 4.5.
- The company reported no notes payable at year-end. Recorded obligations included $2.55 million of current earnout payable and approximately $0.66 million of lease liabilities, including current and long-term portions. Accumulated deficit was $63.91 million.
Material changes and developments
- FY2023 net loss narrowed from 2022, primarily reflecting the absence of the prior-year goodwill impairment, while operating cash use increased.
- Nora Pharma had 52 generic drugs on the Canadian market. The company said 32 additional drugs were scheduled for launch in 2024 and 2025; actual timing and commercial contribution are uncertain.
- Adva-27a development was paused in November 2023 after unfavorable laboratory results. K1.1 mRNA and SBFM-PL4 remained at animal-testing stages; the filing reports no FDA or other regulatory filings for these proprietary candidates.
- After year-end, the company reported a February 2024 public offering with approximately $10 million of gross proceeds, and purchases and cancellation of warrants for approximately $3.14 million in aggregate. These are subsequent events, not FY2023 results.
Outlook, risks and unusual items
- Management estimated that year-end cash would fund pharmaceutical sales operations and R&D for the next 24 months, but stated the estimate is not assured, there are no committed capital sources, and additional funding is anticipated.
- Key risks include continued losses, cash burn and financing needs; generic-drug pricing pressure and competition; dependence on overseas manufacturing and supply chains; regulatory and launch delays; and the early, uncertain status of proprietary drug programs. The filing also cites exposure to a limited number of key customers in its risk discussion, while a financial-statement note says customer concentration risk is not material.
- Nasdaq notified the company in February 2024 that its securities would be removed from listing, subject to appeal. The company appealed, which stayed the action pending a hearing decision, and indicated plans for a reverse stock split to address the minimum-bid-price requirement.
- The CEO’s employment agreement provides for a $10 million payment if the company terminates him without cause and a $2 million payment upon expiration of the agreement.
- The auditor issued an unqualified opinion on the financial statements and reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether the stated 24-month cash runway remains reasonable given operating cash use, planned R&D, and the impact of the February 2024 offering and warrant repurchases.
- Progress, approvals, launch timing and expected economics for the 32 planned generic-product launches, and whether generic pricing or proposed Canadian PharmaCare legislation changes results.
- Updated status of the Nasdaq appeal, reverse split and listing compliance.
- Current share count and potential dilution: the filing reports 28.02 million common shares at year-end but 99.45 million as of March 28, 2024, following subsequent financing activity; outstanding warrants and other securities should also be reviewed.
- The customer-concentration disclosures, and the status of Adva-27a, K1.1 and SBFM-PL4 development, funding and regulatory plans.
- Reconciliation of the CEO’s Series B Preferred Stock holdings: 10,000 shares were reported at year-end, while later beneficial-ownership disclosure reports 130,000 shares after subsequent issuances.